Clinical Trials in Minneapolis

Showing 1941-1960 of 6,957 trials

Remote Trial - Tobacco Product Standard (VLNC)

NCT06442384

The goal of this pilot project is to explore the feasibility of a real-world marketplace study design examining the effects of a reduced nicotine product standard for cigarettes on smoking in the context of a flavor restriction vs. no restriction on e-cigarettes in smokers switched to very low nicotine content cigarettes.

Tobacco Use

Masonic Cancer Center, University of Minnesota11 participantsStarted Sep 2024

Minneapolis, Minnesota, United States

TERMINATEDPhase 1/2< 1 mile

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

NCT03690869

Phase 1: * To confirm the safety and anticipated recommended phase 2 dose (RP2D) of REGN2810 (cemiplimab) for children with recurrent or refractory solid or Central Nervous System (CNS) tumors * To characterize the pharmacokinetics (PK) of REGN2810 given in children with recurrent or refractory solid or CNS tumors Phase 2 (Efficacy Phase): * To confirm the safety and anticipated RP2D of REGN2810 to be given concomitantly with conventionally fractionated or hypofractionated radiation among patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) * To confirm the safety and anticipated RP2D of REGN2810 given concomitantly with conventionally fractionated or hypofractionated radiation among patients with newly diagnosed high-grade glioma (HGG) * To confirm the safety and anticipated RP2D of REGN2810 given concomitantly with re-irradiation in patients with recurrent HGG * To assess PK of REGN2810 in pediatric patients with newly diagnosed DIPG, newly diagnosed HGG, or recurrent HGG when given in combination with radiation * To assess anti-tumor activity of REGN2810 in combination with radiation in improving overall survival at 12 months (OS12) among patients with newly diagnosed DIPG * To assess anti-tumor activity of REGN2810 in combination with radiation in improving progression-free survival at 12 months (PFS12) among patients with newly diagnosed HGG * To assess anti-tumor activity of REGN2810 in combination with radiation in improving overall survival at OS12 among patients with recurrent HGG

Relapsed Solid TumorRefractory Solid TumorRelapsed Central Nervous System Tumor+3 more

Regeneron Pharmaceuticals57 participantsStarted Sep 2018

Los Angeles, California, United States • San Diego, California, United States • San Francisco, California, United States +17 more locations

Remote Trial - Tobacco Product Standard (VLNC)

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Find Trials by Condition in Minneapolis

AB-1002 in Patients With Class III Heart Failure

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Comparing Ankle Fusion to Ankle Replacement

ADH1 and ADH2 Disease Monitoring Study (DMS)

Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

Long Term Follow-up of HPV Vaccine in HIV (CTN 236)

Systane® Complete Preservative Free Lubricant Eye Drops

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Evaluation of Exotropia After Patching the Eye or After Prism Adaptation

Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors